Post by 🟢 Chris Stirling 🟢

Is your regulatory strategy robust enough to secure your next funding round? In 2026, the California biotech sector is facing a leaner, highly disciplined capital market. With a permanent cap on state R&D tax credits and a 34% drop-off in start-up funding in hubs like San Diego, venture capital is no longer a given. Modern investors are highly risk-averse. They are directing capital exclusively toward biotechs with well-defined regulatory pathways and ironclad compliance records. For small biotech business owners, your QARA team is no longer just a cost centre: it is your ultimate funding asset. At Stirling Global, we help emerging life science and medtech businesses scale their compliance divisions efficiently. Whether you need flexible contract specialists to hit upcoming submission milestones or a retained search for permanent regulatory leadership, we have the network to support your journey. Read our full analysis on how to align your hiring strategy with investor expectations: https://lnkd.in/evESbBs2 #LifeSciences #RegulatoryAffairs #QualityAssurance #StirlingGlobal